Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832685 · ClinicalTrials.gov registry record · NA
Neuromodulation of Mind-Wandering in Depression
A NA study, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT04832685: Active NA study, sponsored by Massachusetts General Hospital.
NCT04832685 is a NA study that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832685, a NA study, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that DOWN-modulation of the posterior cingulate cortex (PCC), a key DMN node, will decrease DMN resting state functional connectivity, perfusion, and activation during a cognitive-affective task (description below). The investigators also hypothesize that DOWN-modulation of the PCC will be associated with decreased mind-wandering and increased mindfulness. Finally, the investigators hypothesize that the opposite will be true for UP-modulation of the PCC.
Interventions
- DEVICE BrainSonix Pulsar 1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04832685
The ClinicalTrials.gov registry entry for NCT04832685 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BrainSonix Pulsar 1002 is the first listed.
NCT04832685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04832685 about?
NCT04832685 is a clinical study titled "Neuromodulation of Mind-Wandering in Depression". The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of LIFUP in changing negative cognition in depression. Specifically, the investigators will study if modulating DMN activity can change maladaptive mind-wandering. The investigators hypothesize that D...
What is the current status of trial NCT04832685?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-03-20. Estimated completion is 2026-12.
What interventions are being tested in trial NCT04832685?
The interventions under investigation include: BrainSonix Pulsar 1002 (DEVICE).
Who is sponsoring clinical trial NCT04832685?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.